Moderate Evidence
Research Overview
BT5528 Research for Urothelial Cancer
An evidence-based overview of research examining BT5528 in the context of urothelial cancer. This page synthesizes findings from peer-reviewed literature.
Research Summary
BT5528 has been studied in patients with advanced EphA2-expressing solid tumors, including urothelial cancer. The first-in-human Phase I reported a 6.7% overall response rate and 20% disease control at the recommended Phase 2 dose across all enrolled tumor types. EphA2 is overexpressed in 50-70% of urothelial tumors.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.